Breast Cancer Consensus: The National Comprehensive Cancer Network (NCCN) publishes annual clinical practice guidelines for various malignancies that are recognized and followed by clinicians worldwide. The European Society for Medical Oncology (ESMO ) is Europe’s leading non-profit, professional organization for the advancement of cancer care around the world. American Society of Clinical Oncology (ASCO) BC Guidelines (Breast Cancer Guidelines) Chinese Society of Clinical Oncology Collaborative Center (CSCO) Chinese Anti-Cancer Society Breast Cancer Specialty Committee (CBCS) St. Gallen Consensus (European Consensus), St. Gallen, Switzerland Town Breast Cancer Efficacy Evaluation: Complete remission (complete response (CR) C disappearance of all target lesions, no new lesions, and normal tumor markers, maintained for at least 4 weeks. There are two definitions of complete pathological response (pCR): (1) Generally, it means that no histological evidence of malignancy can be found in the primary breast lesion, or only the in situ cancer component remains; (2) Strictly speaking, pCR means that both the primary breast lesion and the metastatic regional lymph nodes achieve complete pathological remission. Clinical complete response (cCR) Partial response (PR) C ≥ 30% reduction in the sum of the largest diameter of the target lesion, maintained for at least 4 weeks. Stable disease (SD) C The sum of the maximum diameter of the target lesion has not decreased to PR or increased to PD. Progression disease (PD) C The sum of the maximum diameter of the target lesion has increased by at least ≥20% or a new lesion has appeared. Disease-free survival (DFS) Overall survival (OS) Time to tumor treatment failure (TTF). Objective response rate (ORR) ORR = CR + PR clinical benefit rate (CBR): CBR = CR + PR + SD ≥ 24 weeks HR (hazard ratio, risk ratio), risk ratio is the ratio of two risk rates (Hazard Rate). The risk rate is the number of events per unit of time as a percentage of the total number of subjects.